← Leaderboards
Ashley Colemon
Duke University
$126,223
Attributed
$126,223
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $44.9K · FY2022–24$50K$37.5K$25K$12.5K$0
'22
'23
'24
Funding mix
By agency
NIH$126,223 · 1
By mechanism
F31$126,223 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- James W. Vaupel$19,203,791
- John H Sampson$43,413,436
- William J Steinbach$15,812,111
- Myles S Wolf$18,390,362
- Daniel B Mark$29,174,449
Others in their field
Other Rising Stars on “Atac-Seq”
- Linus Tzu-Yen Tsai · Beth Israel Deaconess Medical Center$3,279,626
- Sarah Elizabeth Lutz · University Of Illinois At Chicago$3,110,235
- Ming He · University Of California, San Diego$2,917,239
- Konstantinos Chronis · University Of Illinois At Chicago$2,889,628
- Yue Wang · Florida State University$2,782,476
- Andrew Chris Yang · University Of California, San Francisco$2,531,012
Research focus
Atac-SeqAntitumor ResponseBoneBrainBreast Cancer CellBreast Cancer Cell LineBreast Cancer MetastasisBreast Cancer ModelCancer CellCancer EtiologyCell DeathCell LineCell SurvivalCessation Of LifeChromatinChromatin Remodeling FactorClinical TrialsCombined Modality TherapyCrispr ScreenDrug TargetingEfficacy TestingEnzymesEpigenetic DrugEpigenetic Process
Grant awards (3)
Investigating the Impact of ABL Kinase Signaling on Epigenetic Reprogramming in Metastatic Triple Negative Breast Cancer$41,391
F31 · FY2024 · CA · contact PI
Investigating the Impact of ABL Kinase Signaling on Epigenetic Reprogramming in Metastatic Triple Negative Breast Cancer$39,948
F31 · FY2023 · CA · contact PI
Investigating the Impact of ABL Kinase Signaling on Epigenetic Reprogramming in Metastatic Triple Negative Breast Cancer$44,884
F31 · FY2022 · CA · contact PI